argenx

Industriepark 7

9052 Zwijnaarde

BE

argenx

Foundation date

2009

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan.

Upcoming events

Latest news

  • reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

    Thursday October 21st 2021

  • Mithra announces Estelle® launch in Belgium

    Thursday October 21st 2021

  • Biotalys awarded multi-year grant to develop new biological solutions for cowpea and other legumes

    Wednesday October 20th 2021

Jobs by argenx